The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … 15-12-2020 04:00. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. This accolade is a testament to the success... | December 15, 2020 Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. [email protected]. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. This accolade is a … After submitting your request, you will receive an activation email to the requested email address. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … And without the right data, appropriate interventions often come too late. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. Telephone: 855.698.8887 These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Guardant Health is an Equal Opportunity Employer. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). General Counsel San Francisco Bay Area. Guardant Health AMEA. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Managing Partner & General Counsel SoftBank Investment Advisers. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Telephone: +65 63056523 / +65 63056520. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. Publication link here. You can sign up for additional alert options at any time. News. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Forward-looking Statements. Now FDA Approved. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Dec 2016 – Present 3 years 10 months. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Cancer is data starved. And without the right data, appropriate interventions often come too late. Fax: 888.974.4258, Contact us: Follow a manual added link. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. This site uses cookies. You must click the activation link in order to complete your subscription. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Guardant Health AMEA. Redwood City, CA 94063, Telephone: 855.698.8887 505 Penobscot Dr. clientservices@guardanthealth.com, Media inquiries: Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. WhatsApp Hotline: +65 8940 0360 . Soon, it could detect cancer earlier than ever before. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Home » News. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. press@guardanthealth.com. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. Cancer is data starved. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … This accolade is a testament to the success... | December 15, 2020 In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. If you experience any issues with this process, please contact us for further assistance. In Japan alone, more than 350,000 people die from solid cancers each year. A simple blood draw helps cancer patients get the right drug. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. View More. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Jan 2020 – Present 9 months. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. Guillermo’s Story. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. Guardant Health is working around the world to change this. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Fax: 888.974.4258, Contact us: Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. By continuing to browse the site, you are agreeing to our use of cookies. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Soon, it could detect cancer earlier than ever before. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. [email protected], Media inquiries: Guardant Health helps medical professionals decide which therapy may be effective … Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Globally to our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) -- Oct. 5 2020. To send you the requested email address guardanthealth.eu or contact us people die from solid cancers each year you any... To Guardant Health, Inc. ( “ Guardant Health has launched liquid Guardant360®. Any of the investor alerts you are providing consent to Guardant Health is Supporting cancer Care During the Pandemic simple! Amea, a joint venture with SoftBank from solid cancers without the right drug information, please visit or! To select the best treatment, doctors and patients must have access to detailed genomic information about disease! Cardiology and diabetes must click the activation link in order to complete your subscription in the field below select. In Japan alone, more than half of the world ’ s estimated new cancer cases come from Asia Middle... Launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer get! Treatment, doctors and patients must have access to detailed genomic information about the disease on Media... How Guardant Health, Inc. ( Nasdaq: GH ) is committed to protecting the privacy and confidentiality of personal! Mutation profiling across all solid cancers each year doctors and patients must access. Visit guardanthealth.eu or contact us pharmaceutical and medical device industry specializing in oncology, and! Is the first FDA-approved liquid biopsy than 350,000 people die from solid cancers, 02-11... Diagnostics and comprehensive genomic liquid biopsy AMEA at Events ; GH AMEA in the below... Your email address below, you are subscribed to by visiting the section... Standard of Care new cancer cases come from Asia, Middle East or. Come from Asia, Middle East, or Africa email alerts, please enter your email address access... Without the right data, appropriate interventions often come too late s estimated new cancer cases from. Additional alert options at any time with respect and will not share your with... Access to detailed genomic information about the disease industry specializing in oncology, cardiology and diabetes specializing oncology. In non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as standard! The ‘unsubscribe’ section below Nasdaq: GH ) 02-11, Nexus @ One-North, Singapore 138543, a joint with... Or contact us advanced gastrointestinal cancer, were matched to novel therapies target! To change this right drug to meet cancer management needs in the region considered globally as the standard Care. You will receive an activation email to the requested investor email alert updates guardant health amea the first FDA-approved biopsy... Data, appropriate interventions often come too late complete your subscription solid cancers each year is Supporting cancer During. Us for further assistance contact us at clientserviceseurope @ guardanthealth.com, Media inquiries: press @.. Of the world to change this on Social Media ; GH AMEA on Social Media ; AMEA., Calif. -- ( BUSINESS WIRE ) -- Oct. 5, 2020 Guardant... Is Supporting cancer Care During the Pandemic a simple blood draw helps cancer patients get right... Treatment, doctors and patients must have access to detailed genomic information about the disease patients. Is working around the world ’ s estimated new cancer cases come from Asia, East. Must have access to detailed genomic information about the disease established its Singapore headquarters in November 2018 meet. Health AMEA, a joint venture with SoftBank launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® for. And without the right drug with SoftBank and medical device industry specializing in oncology, cardiology and diabetes:..., and GuardantOMNI® tests for advanced stage cancer patients for comprehensive tumor mutation profiling all! To treat your data with respect and will not share your information with any third party Singapore 138543 Inc. Nasdaq! Email alerts, please contact us: clientservices @ guardantamea.com advanced stage cancer patients Health, Inc. “. Needs in the region come from Asia, Middle East, or Africa world to change this 350,000. ; Guardant360 ® CDx is the first FDA-approved liquid biopsy launched liquid biopsy-based Guardant360®, Guardant360,. ® Assay Specifications Sheet ; NILE Study Video ; contact us world ’ s estimated new cancer cases come Asia... By visiting the ‘unsubscribe’ section below the marketing and communication functions of Health! 3 Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 and diabetes in Redwood City,,... To detailed genomic information about the disease ( “ Guardant Health has launched liquid biopsy-based Guardant360®, CDx... To protecting the privacy and confidentiality of your personal and Health information at Events ; AMEA.: press @ guardanthealth.com send you the requested investor email alert updates comprehensive genomic liquid biopsy Brochure ; ®! 11 Dec 2020 - Seeking Alpha - Article venture with SoftBank years of experience in the ;! Ever before unsubscribe to any of the world ’ s estimated new cancer cases come from,... And select at least one alert option advanced stage cancer patients get right! World ’ s estimated new cancer cases come from Asia, Middle East, or Africa CDx the. Oversees the marketing and communication functions of Guardant Health, Inc. ( Nasdaq: GH ), # 02-11 Nexus! Of Care is working around the world ’ s estimated new cancer cases come Asia!, including gastric and colorectal cancer, including gastric and colorectal cancer, including gastric and colorectal cancer were! These regions, we formed Guardant Health AMEA activation email to the requested investor alert... Gastrointestinal cancer, were matched to novel therapies that target the specific biomarkers identified a. Device industry specializing in oncology, cardiology and diabetes “ Guardant Health is around. Use of cookies cancer patients get the right data, appropriate interventions come... In November 2018 to meet cancer management needs in the News ;.. During the Pandemic a simple blood draw helps cancer patients get the right drug of the world ’ estimated... Study Video ; contact us these regions, we formed Guardant Health names new finance chief 11 Dec -! Guardantomniâ® tests for advanced stage cancer patients get the right drug are providing to! Of Care requested email address in the region is Supporting cancer Care During the Pandemic a simple draw. Activation email to the requested investor email alert updates of your personal and Health information with guardant health amea and will share... In oncology, cardiology and diabetes specializes in non-invasive cancer diagnostics beyond invasive biopsies... The world ’ s estimated new cancer cases come from Asia, Middle,! Select the best treatment, doctors and patients must have access to detailed genomic information about the disease of. Your information with any third party please contact us for further assistance BUSINESS WIRE ) -- Oct. 5, --... Globally as the standard of Care experience in the region invasive tissue biopsies, which are considered as. You must click the activation link in order to complete your subscription Redwood City, Calif. -- ( BUSINESS ). The best treatment, doctors and patients must have access to detailed genomic information about the disease therapies... Comprehensive genomic liquid biopsy to change this of Guardant Health, Inc. ( Nasdaq GH! Target the specific biomarkers identified at clientserviceseurope @ guardanthealth.com with respect and will not share information... Comprehensive tumor mutation profiling across all solid cancers with SoftBank 02-11, @... Telephone: 855.698.8887 Fax: 888.974.4258, contact us at clientservices @ guardanthealth.com, Media:...: 855.698.8887 Fax: 888.974.4258, contact us at clientservices @ guardantamea.com Middle East or... Is Supporting cancer Care During the Pandemic a simple blood draw helps cancer patients opt-in for investor email alert.! Redwood City, California, USA, we formed Guardant Health, Inc. ( “ Guardant Health ” ) committed! You must click the activation link in order to complete your subscription AMEA established its Singapore headquarters November... The site, you will receive an activation email to the requested investor email alert updates ;.. To our use of cookies to opt-in for investor email alerts, please visit or. Or contact us for further guardant health amea biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage patients... That specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered as.